1. Scrip
  2. >>Business
  3. >>Financing

Forbion Will Use New Fund To Rescue Struggling Biotechs

European VC Raises €1.35bn

 
• By Andrew McConaghie

The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.

Biotech
• Source: Shutterstock

The impressive €1.35bn ($1.5bn) sum that Forbion raised recently for its two newest funds demonstrates institutional investor belief in the sector, the European venture capital firm said, even while many public and private biotechs struggle as funding dries up.

Headquartered in Naarden, the Netherlands, and Munich, Germany, the European life sciences VC firm has just closed its Forbion Ventures...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.